PDCD1 and hepatocellular carcinoma: In conclusion, the combination of TACE, lenvatinib, and a PD-1 inhibitor may offer synergistic antitumor activity, contributing to improved clinical outcomes in patients with intermediate-stage HCC exceeding the up-to-7 criteria.